Eli Lilly invests $40M in Absci for AI-designed injectable antibody ABS-201
Eli Lilly invested $40 million in Absci Corporation to advance ABS-201, an AI-designed injectable antibody targeting hair loss and endometriosis. The investment was part of a $100 million equity round…